It is made up of highly specialized endothelial cells. The vessels of the blood-brain barrier consist of specialized endothelial cells that line the brain capillaries of the vascular system, have no pore windows and enable a rapid exchange of molecules between vessels and tissues. The blood-brain barrier protects the nerve tissue from harmful chemicals and ensures a stable environment. Unfortunately, this barrier is so effective in blocking the passage of foreign matter that it often prevents life-saving drugs from entering to treat problems such as injury and illness.
Get a Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/4183
Therefore, the discovery of new modalities that enable the effective delivery of drugs and bio-macromolecules to the central nervous system (CNS) is of great importance in the treatment of neurodegenerative diseases.
Neurodegeneration and neuroinflammation are key events in CNS disorders such as stroke, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. However, drugs used to treat the CNS, such as neurotrophic factors, including BDNF, EPO (erythropoietin), and anti-inflammatory antibodies (such as Enbrel and Remicade), do not cross the blood-brain barrier in effective therapeutic amounts.
Get a bespoke scope that suits your needs. Ask an Expert – [email protected]
North America dominates the world market for blood brain barrier technologies given the rising incidence of neurological diseases and the growing geriatric population in the region. Asia is expected to show high growth rates in the global blood-brain barrier technology market over the next five years, with China and India being the fastest growing markets in the Asia-Pacific region. The main driving forces behind the blood-brain barrier technology market in developing countries are the large patient pool, increasing awareness of the disease, improving health infrastructure, and increasing government funding in the region.
For a full list of market participants, request the table of contents here @ https://www.persistencemarketresearch.com/toc/4183
Increasing prevalence of neurological diseases such as meningitis, multiple sclerosis, Parkinson’s disease and encephalitis, growing geriatric population, increasing health care spending, increasing investment in research and development for the development of new drugs and delivery devices, growing health care awareness, and increasing numerous initiatives by various governments and government organizations are some of the key factors driving the global blood brain barrier technology market to grow.
However, complex regulatory frameworks for drug approval in most countries and long drug approval times due to insufficient knowledge of the brain are major obstacles to the growth of the global blood-brain barrier technology market.
Innovation in drugs and delivery devices to cross the blood-brain barrier would help create opportunities for the global blood-brain barrier technology market. The most important companies active in the global blood-brain barrier technology market are Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., bioasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical NV, NeuroVive Pharmaceutical AB, and ArmaGen.
Book in advance now for exclusive analyst support @ https://www.persistencemarketresearch.com/checkout/4183
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
US-Tel. – +1-646-568-7751
US-Canada Toll Free – 800-961-0353
Sales – [email protected]
–
